Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow OPK by emailGet an email when OPK pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OPK, unsubscribe in one click. Privacy
📣 What OPK Says Is Next
at the end of 2026 · “OPKO Biologics presented preclinical data on long acting Growth Hormone Receptor Antagonist OPK8801001 at the Endocrine Society (ENDO) 2026 annual meeting, with plans to advance the program to clinical trials at the end of 2026.”
Company press release, Jul 27, 2026 · SEC filing
first half of 2027 · “We expect to report initial safety, tolerability, pharmacokinetic and immune data in the first half of 2027.”
Company press release, Jul 27, 2026 · SEC filing
this year · “ModeX presented data on multispecific antibody targeted in vivo CAR T cell programs at the American Society of Gene + Cell Therapy (ASGCT) Annual Meeting, with plans to enter Phase 1 studies later this year or in early 2027.”
Company press release, Jul 27, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full OPK picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OPK and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.